Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 7/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.53 |
| ▸ | JAK3 | P52333 | 5/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.53 |
| ▸ | PLK4 | O00444 | 4/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 4/20 | 0.53 |
| ▸ | CDK1 | P06493 | 4/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | TYK2 | P29597 | 4/20 | 0.53 |
| ▸ | CLK2 | P49760 | 4/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.53 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007120 | 0.79 | GSK3B (0.69) | GSK3BJAK2ROCK1ROCK2CDK8 | |
| SCHEMBL28612625 | 0.78 | CSNK2A1 (0.55) | GSK3BJAK2CLK4JAK3ROCK1 | |
| SCHEMBL4003944 | 0.77 | CDK2 (0.53) | GSK3BJAK2CLK4JAK3ROCK1 | |
| SCHEMBL11701839 | 0.77 | GSK3B (0.66) | GSK3BJAK2ROCK1ROCK2AXL | |
| SCHEMBL627302 | 0.76 | GSK3B (0.60) | GSK3BJAK2CLK4JAK3LIMK1 | |
| SCHEMBL13789198 | 0.72 | GSK3B (0.59) | GSK3BJAK2JAK1FADS1 | |
| SCHEMBL1461484 | 0.71 | GSK3B (0.70) | GSK3BCLK4PLK4DAPK3CDK1 | |
| SCHEMBL118573 | 0.70 | JAK2 (0.64) | GSK3BJAK2CLK4JAK3ROCK1 | |
| SCHEMBL1460931 | 0.70 | ITK (0.59) | ITKMAP2K4 | |
| SCHEMBL4498676 | 0.70 | GSK3B (0.56) | GSK3BFADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | GSK3B 75/4885JAK2 262/4885CLK4 608/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | GSK3B 100/4885JAK2 272/4885CLK4 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.